聚菲林H通过结合膜胆固醇来抑制ABCB1和ABCC3的作用,逆转乳腺癌中帕克利塔塞尔耐药性的作用
Zheng Ye1, Chao Hong1,2, Min Jiang1
1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
聚菲林H (PPH) 通过向富含胆固醇的脂质来克服乳腺癌中帕克利塔塞尔 (PTX) 耐药性. 这破坏了ATP结合盒 (ABC) 载体,恢复了PTX的敏感性,并增强了瘤抑制.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 乳腺癌是女性癌症死亡的主要原因.
- 帕克利塔塞尔 (PTX) 是一种关键的化疗,但耐药性限制了它的有效性.
- ATP结合盒 (ABC) 载体驱动化学阻力,需要多目标策略.
研究的目的:
- 研究一种针对胆固醇的策略,以克服乳腺癌中PTX抵抗.
- 评估多林H (PPH) 作为逆转PTX耐药性的潜在药物.
主要方法:
- 建立了一种抗PTX的乳腺癌细胞系 (MCF-7/PTX),具有ABCB1/ABCC3上调和胆固醇.
- 对于胆固醇结合和对ABC载体的影响,PPH与洛瓦斯塔丁进行了比较.
- 评估了PPH对药物流量,细胞内PTX水平和瘤生长 in vitro 和 in vivo 的影响.
主要成果:
- PPH直接与膜胆固醇结合,破坏脂质并降低ABCB1/ABCC3.3的调节.
- PPH减少了药物排放,增加了细胞内PTX,并恢复了敏感性.
- PPH在逆转抗药性和抑制瘤生长方面表现出比洛瓦斯塔丁更高的疗效.
结论:
- PPH通过向胆固醇-脂质,以抑制多个ABC转运器,有效地逆转PTX抵抗.
- 基于PTX的乳腺癌治疗中,PPH显示为一种更安全的辅助疗法.
- 这种方法为克服其他恶性瘤药物耐药性的框架.
相关概念视频
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K


